Screener
Myriad Genetics MYGN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Myriad Genetics’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 6:05 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000899923-26-000038
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Proceeds from revolving credit facility | — | 40.0 |
| Repayment of revolving credit facility | — | (20.5) |
| Payment on finance leases | (0.1) | (0.1) |
| Net cash (used in) provided by financing activities | (3.0) | 13.6 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | (0.1) | 0.1 |
| Net decrease in cash, cash equivalents, and restricted cash | (25.3) | (10.9) |
| Cash, cash equivalents, and restricted cash at beginning of the period | 151.3 | 111.9 |
| Cash, cash equivalents, and restricted cash at end of the period | $126.0 | $101.0 |
Item 1. Financial Statements.
FAQ
- What is Myriad Genetics's cash & equivalents?
- Myriad Genetics (MYGN) reported cash & equivalents of $126M in Q1 2026.
- How has Myriad Genetics's cash & equivalents changed year-over-year?
- Myriad Genetics's cash & equivalents increased by 24.8% year-over-year, from $101M to $126M.
- What is the long-term trend for Myriad Genetics's cash & equivalents?
- Over 5 years (2020 to 2025), Myriad Genetics's cash & equivalents has grown at a 5.3% compound annual growth rate (CAGR), from $117M to $151.3M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Myriad Genetics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude